Why Indian Drugmakers Are Losing Pricing Power In The US


Date:

(MENAFN- Live Mint) Indian drugmakers are losing pricing power in the US, their largest market, as buyer concentration and intensifying competition squeeze sales and margins. In the July-September 2026 quarter, Cipla's North America revenue fell 19% in rupee terms as sales of generic Revlimid, a blood cancer drug, declined amid competition. Revlimid also weighed on Dr. Reddy's North America sales, while Lupin's US sales fell 13% from the April-June quarter after it lost exclusivity on Tolvaptan and Mirabegron.

MENAFN17112026007365015876ID1111972921


Live Mint

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search